Is Repare Therapeutics Stock a Good Investment?
Repare Therapeutics Investment Advice | RPTX |
- Examine Repare Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Repare Therapeutics' leadership team and their track record. Good management can help Repare Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Repare Therapeutics' business and its evolving consumer preferences.
- Compare Repare Therapeutics' performance and market position to its competitors. Analyze how Repare Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Repare Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Repare Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Repare Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Repare Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Repare Therapeutics Stock
Researching Repare Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 84.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Repare Therapeutics recorded a loss per share of 1.99. The entity had not issued any dividends in recent years.
To determine if Repare Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Repare Therapeutics' research are outlined below:
| Repare Therapeutics generated a negative expected return over the last 90 days | |
| Repare Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 51.13 M. Net Loss for the year was (93.8 M) with profit before overhead, payroll, taxes, and interest of 15.11 M. | |
| Repare Therapeutics currently holds about 282.09 M in cash with (127.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Repare Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Analysts Revenue Estimates For Repare Therapeutics Inc. Are Surging Higher |
Repare Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Repare Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Repare Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Repare Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Repare Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-13 | 2021-03-31 | -0.51 | -0.58 | -0.07 | 13 | ||
2024-11-07 | 2024-09-30 | -0.8625 | -0.7745 | 0.088 | 10 | ||
2021-08-12 | 2021-06-30 | -0.6 | -0.71 | -0.11 | 18 | ||
2021-11-10 | 2021-09-30 | -0.71 | -0.83 | -0.12 | 16 | ||
2024-02-28 | 2023-12-31 | -0.36 | -0.67 | -0.31 | 86 | ||
2023-11-09 | 2023-09-30 | -0.86 | -0.45 | 0.41 | 47 | ||
2023-08-09 | 2023-06-30 | -0.78 | -0.28 | 0.5 | 64 | ||
2024-05-07 | 2024-03-31 | -0.7833 | 0.3 | 1.0833 | 138 |
Know Repare Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Repare Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repare Therapeutics backward and forwards among themselves. Repare Therapeutics' institutional investor refers to the entity that pools money to purchase Repare Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nikko Asset Management Americas Inc | 2024-06-30 | 277.2 K | Millennium Management Llc | 2024-06-30 | 249.5 K | Sumitomo Mitsui Trust Group Inc | 2024-09-30 | 249.2 K | Gsa Capital Partners Llp | 2024-09-30 | 240.5 K | Affinity Asset Advisors, Llc | 2024-09-30 | 173.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 149.6 K | Squarepoint Ops Llc | 2024-06-30 | 143 K | Blackrock Inc | 2024-06-30 | 141.8 K | Citadel Advisors Llc | 2024-06-30 | 140.4 K | Bvf Inc | 2024-09-30 | 10.3 M | Blue Owl Capital Holdings Lp | 2024-06-30 | 3.4 M |
Repare Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 119.46 M.Market Cap |
|
Repare Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.44) | (0.42) |
Determining Repare Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Repare Therapeutics is a good buy. For example, gross profit margin measures Repare Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Repare Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Repare Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Repare Therapeutics. Check Repare Therapeutics' Beneish M Score to see the likelihood of Repare Therapeutics' management manipulating its earnings.
Evaluate Repare Therapeutics' management efficiency
Repare Therapeutics has return on total asset (ROA) of (0.2339) % which means that it has lost $0.2339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4117) %, meaning that it created substantial loss on money invested by shareholders. Repare Therapeutics' management efficiency ratios could be used to measure how well Repare Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Repare Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 2.8 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 173 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.04 | 3.26 | |
| Tangible Book Value Per Share | 5.04 | 3.26 | |
| Enterprise Value Over EBITDA | (1.75) | (1.83) | |
| Price Book Value Ratio | 1.45 | 1.52 | |
| Enterprise Value Multiple | (1.75) | (1.83) | |
| Price Fair Value | 1.45 | 1.52 | |
| Enterprise Value | 199.4 M | 189.5 M |
Understanding the operational decisions made by Repare Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.713 |
Basic technical analysis of Repare Stock
As of the 24th of November, Repare Therapeutics holds the Risk Adjusted Performance of 0.0102, semi deviation of 3.51, and Coefficient Of Variation of 40232.04. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Repare Therapeutics, as well as the relationship between them.Repare Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repare Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repare Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repare Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repare Therapeutics' Outstanding Corporate Bonds
Repare Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Repare Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Repare bonds can be classified according to their maturity, which is the date when Repare Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SCGAU 5125 24 SEP 80 Corp BondUS76025LAB09 | View | |
| SCGAU 475 24 SEP 80 Corp BondUS76025LAA26 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Repare Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Repare Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0102 | |||
| Market Risk Adjusted Performance | 0.0111 | |||
| Mean Deviation | 3.24 | |||
| Semi Deviation | 3.51 | |||
| Downside Deviation | 3.71 | |||
| Coefficient Of Variation | 40232.04 | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.82 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.70) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.0011 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (6.43) | |||
| Potential Upside | 7.96 | |||
| Downside Variance | 13.75 | |||
| Semi Variance | 12.33 | |||
| Expected Short fall | (4.12) | |||
| Skewness | 1.09 | |||
| Kurtosis | 2.73 |
| Risk Adjusted Performance | 0.0102 | |||
| Market Risk Adjusted Performance | 0.0111 | |||
| Mean Deviation | 3.24 | |||
| Semi Deviation | 3.51 | |||
| Downside Deviation | 3.71 | |||
| Coefficient Of Variation | 40232.04 | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.82 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.70) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.0011 | |||
| Maximum Drawdown | 25.67 | |||
| Value At Risk | (6.43) | |||
| Potential Upside | 7.96 | |||
| Downside Variance | 13.75 | |||
| Semi Variance | 12.33 | |||
| Expected Short fall | (4.12) | |||
| Skewness | 1.09 | |||
| Kurtosis | 2.73 |
Consider Repare Therapeutics' intraday indicators
Repare Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Repare Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Repare Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 20th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify |
Repare Stock media impact
Far too much social signal, news, headlines, and media speculation about Repare Therapeutics that are available to investors today. That information is available publicly through Repare media outlets and privately through word of mouth or via Repare internal channels. However, regardless of the origin, that massive amount of Repare data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Repare Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Repare Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Repare Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Repare Therapeutics alpha.
Repare Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Repare Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Repare Therapeutics Corporate Management
| Michael Zinda | Executive Officer | Profile | |
| Maria MD | Executive Officer | Profile | |
| Agnel Sfeir | CoFounder | Profile | |
| Cameron Black | Executive Discovery | Profile | |
| Kim Seth | Executive Officer | Profile | |
| Philip Herman | Ex Devel | Profile | |
| Daniel Belanger | Executive Resource | Profile |
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.